Monograph Details
|
|
Respiratory Tract
> Lung surfactants/mucolytics
|
|
SURVANTA |
| Manufacturer |
|
Abbott Nutrition |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Lung surfactant. |
| Generic Name |
|
Beractant (as phospholipids) 25mg/mL; susp for intratracheal administration; preservative-free. |
| Indications |
|
Prevention and treatment of respiratory distress syndrome (RDS) in premature infants. |
| Children |
|
See literature for dosing chart, administration, and additional support procedures. 100mg of phospholipids (4mL)/kg birth weight per dose, by intratracheal administration; max 4 doses, at 6 hour intervals in the first 48 hours after birth. Rescue: give 1st dose as soon as possible after infant is placed on mechanical ventilation for treatment of RDS. Prevention: give 1st dose as soon as possible after birth, preferably within 15 minutes. Avoid suctioning for 1 hour after treatment, unless significant airway obstruction occurs. Retreatment is determined by continued respiratory distress. Get radiographic confirmation of RDS in those infants given preventative dose before giving additional doses. |
| Precautions |
|
Interrupt dosing if bradycardia or oxygen desaturation occurs; treat; resume after stabilization. Monitor oxygenation, carbon dioxide, and clinical condition frequently and carefully. |
| Adverse Reactions |
|
Dosing procedure reactions including oxygen desaturation and bradycardia, rales, moist breath sounds, sepsis, intracranial hemorrhage. |
| How Supplied |
|
Vials (4mL, 8mL)—1 |
|
|
|
|
